foscarnet has been researched along with Thrombopenia in 3 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Foscarnet is a reasonable first line anti CMV agent in this setting." | 6.46 | CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature. ( Chajek-Shaul, T; Hershcovici, T; Koslowsky, B; Wolf, D; Yaari, S, 2010) |
| "During study treatment, severe neutropenia (< 0." | 2.70 | Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. ( Cordonnier, C; Einsele, H; Engelhard, D; Finke, J; Lee, J; Link, H; Ljungman, P; Reusser, P; Rovira, M; Volin, L, 2002) |
| "Foscarnet is a reasonable first line anti CMV agent in this setting." | 2.46 | CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature. ( Chajek-Shaul, T; Hershcovici, T; Koslowsky, B; Wolf, D; Yaari, S, 2010) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yaari, S | 1 |
| Koslowsky, B | 1 |
| Wolf, D | 1 |
| Chajek-Shaul, T | 1 |
| Hershcovici, T | 1 |
| Reusser, P | 1 |
| Einsele, H | 1 |
| Lee, J | 1 |
| Volin, L | 1 |
| Rovira, M | 1 |
| Engelhard, D | 1 |
| Finke, J | 1 |
| Cordonnier, C | 1 |
| Link, H | 1 |
| Ljungman, P | 1 |
| Peters, BS | 1 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 1 |
| Harris, JR | 1 |
| Pinching, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant[NCT00386412] | Phase 2 | 132 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for foscarnet and Thrombopenia
| Article | Year |
|---|---|
CMV-related thrombocytopenia treated with foscarnet: a case series and review of the literature.
Topics: Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combination; Fem | 2010 |
1 trial available for foscarnet and Thrombopenia
| Article | Year |
|---|---|
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Child; Cytomegalovirus Infections; Disease-Free Survival; Drug | 2002 |
1 other study available for foscarnet and Thrombopenia
| Article | Year |
|---|---|
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |